An analyst has a 38-residue peptide with a reverse-phase HPLC trace showing a single sharp main peak at 98% area. A colleague then asks how much of that peptide was present as single molecules once it sat in buffer. The purity trace cannot answer that. Size exclusion chromatography, usually shortened to SEC, is the technique built for exactly that question.
Two different questions about the same vial
A reverse-phase purity measurement asks what fraction of the detected material is the intended sequence. It separates the target from deletion sequences, truncations and other synthesis by-products that differ in hydrophobicity. Its acidified water/acetonitrile gradient is harsh on weak associations. Most non-covalent dimers and oligomers fall apart under those conditions long before they reach the detector, so the trace reports the chemical composition of the sample, not its association state.
SEC asks a different question: in a mild, mostly aqueous buffer near neutral pH, how is the material distributed by size? Monomer, dimer, higher oligomers and soluble aggregates can survive that environment and appear as separate peaks, with the larger species eluting first. Put simply, reverse phase tells you whether you have the right molecule; SEC tells you whether that molecule is traveling alone.
Covalently linked aggregates, such as a disulfide-bridged dimer, can appear under either method; the non-covalent population is the one only SEC reveals.
How the separation works
An SEC column is packed with porous particles. The mobile phase is pumped through at a constant composition, with no gradient. A molecule that is small relative to the pores can diffuse into them and explore a large internal volume, so it takes a long route and leaves late. A molecule too large to enter any pore is confined to the spaces between particles and exits early.
The whole separation happens within one column volume of eluent, and ideally nothing binds to the packing. That gentleness is why SEC can report fragile associations that reverse phase would destroy.
The usable window
Every SEC column has two hard boundaries. The exclusion limit corresponds to the void volume: anything larger than the biggest pores elutes there, all together and unresolved. The total permeation limit corresponds to the point where molecules small enough to enter every pore elute, again all together. Only species sized between those two limits are separated.
This is the single most common reason an SEC run on a short peptide produces one featureless peak. If the column’s pore size places the peptide and its likely oligomers at the permeation limit, they co-elute no matter how good the column is. Pore size selection is the first method decision, not a detail.
Reading size, not mass
To convert elution volume into a molecular weight, laboratories run a set of calibration standards of known mass and fit a curve. The number that comes out should always be called an apparent molecular weight, because SEC responds to hydrodynamic size, the effective volume a molecule occupies in solution, rather than to mass.
That distinction matters a great deal for peptides. Calibration standards are usually compact, globular proteins. Many peptides are flexible and largely unstructured in aqueous buffer, and an extended chain occupies more volume than a folded protein of the same mass. The result is an apparent weight that is systematically too high. SEC is therefore a tool for comparing relative size populations within a sample, not for confirming identity; that job belongs to mass spectrometry.
When the column is not neutral
The ideal SEC packing is completely inert. Real packings carry some residual surface charge, and peptides are charged too, so electrostatic interaction competes with the size mechanism. A strongly basic peptide can be attracted to a negatively charged surface and elute later than its size predicts, looking smaller. An acidic peptide can be repelled and elute earlier, looking larger.
The usual countermeasure is to run with a buffered salt at moderate ionic strength, such as a phosphate or acetate system, sometimes with a small proportion of organic modifier to suppress hydrophobic interaction. The mobile phase then becomes part of the result, so SEC data are only comparable between runs made under identical conditions.
Where SEC results go wrong
SEC can under-report aggregation in several well-known ways:
| Problem | What happens | How analysts check for it |
|---|---|---|
| Dilution on the column | The sample band spreads and dilutes as it travels; a reversible, concentration-dependent oligomer may dissociate before detection. | Compare runs at different loading concentrations; a changing oligomer fraction points to a reversible association. |
| Adsorptive loss | Aggregates stick to frits or packing and never elute, so the chromatogram looks cleaner than the sample. | Compare total peak area against a load made without the column in line; missing area is a result, not noise. |
| Insoluble material | Anything removed by filtration or centrifugation before loading is never seen. | State in the report that the data describe the soluble fraction only. |
| Limited resolution | Species that differ in size by less than about a factor of two are hard to separate on a single column. | Interpret shoulders cautiously; consider an orthogonal size method. |
Choosing a detector
UV absorbance is the default detector, and it brings the same caveat as in any peptide chromatography: response depends on the chromophores present, so peak area is not a direct measure of mass. Large aggregates also scatter light, which can inflate their apparent absorbance. Refractive index detection follows mass concentration more closely but is less sensitive.
Adding an in-line multi-angle light scattering detector changes the nature of the measurement. Molar mass is calculated from the scattered light itself, without a calibration curve, which removes the shape problem described above. It does, however, need an accurate concentration at each point from a detector running alongside.
Why short peptides rarely get an SEC result
Buyers sometimes ask why a certificate for a short synthetic peptide shows a reverse-phase trace but no size exclusion data. The answer is that for a short chain, the impurities that matter are deletion sequences, truncated sequences, incompletely deprotected species and residual reagents, all described in peptide synthesis impurities. Those species are almost the same size as the target, so SEC cannot separate them, while a reverse-phase gradient can. Running a fifteen-residue peptide through an SEC column typically yields one peak and no new information.
SEC earns its place as chains get longer, as secondary or tertiary structure becomes relevant, and where aggregation state is a question in its own right.
At Battle Born, No product goes unlisted: each has an independent reverse-phase HPLC result on its page. That is a purity measurement, and it should be read as one; guidance on interpreting it is in how to read an HPLC chromatogram.
Questions
Can SEC replace a reverse-phase purity test?
No. SEC separates by size, and most synthesis-related impurities in a peptide are nearly the same size as the target. It complements a reverse-phase result by describing association state; it does not measure chemical purity.
Why does my peptide look twice its real size on SEC?
Most likely because the column was calibrated with globular proteins and the peptide is extended in solution. SEC reports an apparent molecular weight based on hydrodynamic size, which runs high for flexible chains.
Does a single SEC peak prove there are no aggregates?
Not on its own. Reversible oligomers can dissociate as the sample dilutes, aggregates can adsorb and never elute, and insoluble material is removed before loading.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.